UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

           ---------------------------------------------------------


                                    FORM 8-K


                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


         Date of Report (Date of earliest event reported): June 14, 2004


                               ENZO BIOCHEM, INC.
               (Exact Name of Registrant as Specified in Charter)


            New York                       001-09974             13-2866202
(State or Other Jurisdiction of    (Commission File Number)   (I.R.S. Employer
 Incorporation or Organization)                              Identification No.)


               60 Executive Boulevard, Farmingdale, New York 11735
               (Address of Principal Executive Offices) (Zip Code)


       Registrant's telephone number, including area code: (631) 755-5500


                                 NOT APPLICABLE

                                 --------------

          (Former name or former address, if changed since last report)


           ---------------------------------------------------------


ITEM 12.  RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

         On June 14, 2004, the Registrant issued a press release announcing its
operating results for the fiscal quarter ended April 30, 2004. A copy of the
press release is furnished as Exhibit 99.1 to this Current Report.

         The information in this Current Report and the exhibits attached hereto
are being "furnished" hereunder and shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), nor shall they be deemed incorporated by reference into any filings made
by the Registrant with the Securities and Exchange Commission under the Exchange
Act or the Securities Act of 1933, as amended, except as shall be expressly set
forth by specific reference in such filings.







                                        2


                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  June 14, 2004                          Enzo Biochem, Inc.


                                              By: /s/ Barry Weiner
                                              ----------------------------------
                                              Name:  Barry Weiner
                                              Title: Chief Financial Officer







                                        3


                                 EXHIBIT INDEX


EXHIBIT                 DESCRIPTION
- -------                 -----------

 99.1                   Registrant's press release dated June 14, 2004
                        announcing operating results for the fiscal quarter
                        ended April 30, 2004.*


* Furnished herewith.